BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Fauci: Moderna COVID-19 Phase III Trial to Begin in July with 30,000 Patients

  Of the Phase III trial, Fauci indicated that the majority of trial participants will be between the ages of 18 and 55, but will include elderly Americans that are most at risk of serious illness from COVID-19.

  June 3, 2020

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Irish Biotech Company Shorla Raises $8.3 Million Series A

  The round was led by Seroba Life Sciences, a European venture capital firm in Dublin.

  June 3, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  ‘Operation Warp Speed’ Narrows List of Potential COVID-19 Vaccine Candidates Down to Five

  Less than one month after the White House zeroed in on 14 vaccine candidates for COVID-19, the administration has narrowed that list even more to five potential treatments for the prevention of the novel coronavirus.

  June 3, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  NodThera Secures $55 Million to Develop NLRP3 Inflammasome Inhibitors

  U.K.-based NodThera is building up its war chest to develop therapies for diseases driven by chronic inflammation.

  June 3, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  When Will a COVID-19 Vaccine be Ready… and Why Then?

  Industry experts say a vaccine against the SARS-CoV-2 virus will either be ready this fall, at the end of the year or 18 months from now, depending on the vaccine and how they define “ready.”

  June 3, 2020

   · 

  5 min read

   · 

  Gail Dutton
• 

  FDA

  FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug Arzerra

  On Tuesday, the FDA extended its review of the Supplemental Biologics License Application for Arzerra in this indication by three months.

  June 3, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent

  Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020.

  June 3, 2020

   · 

  3 min read

   · 

  Gail Dutton
• 

  BioSpace Global Roundup, June 4

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

  June 3, 2020

   · 

  6 min read

   · 

  Alex Keown
• 

  Drug Development

  Biopharma Update on the Novel Coronavirus: June 3

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 3, 2020.

  June 3, 2020

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  Latest COVID-19 Research Provides Insight on Antibodies, ACE2 and How the Disease Enters the Body

  In its ongoing examination of COVID-19 related research, the journal Nature has provided updates on several scientific papers assessing diagnostics related to the detection of the virus as well as questions surrounding antibody testing and the likely way the virus enters the body.

  June 3, 2020

   · 

  2 min read

   · 

  Alex Keown